Search Results

Download scoring documents for this measure. BACK FLSI Scoring Downloads Download DOC

Download scoring documents for this measure. BACK FACT-BRM Scoring Downloads Download DOC

FAACT Functional Assessment of Anorexia/Cachexia Treatment For patients with Anorexia/Cachexia LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Anorexia/Cachexia Therapy (FAACT) was designed to measure general aspects of quality of life (QOL) as well as specific anorexia/cachexia-related concerns. It includes the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) and a 12 item subscale that specifically measures the symptoms and concerns of patients with anorexia/cachexia (A/CS). The A/CS subscale can be used in conjunction with the FACT-G or as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). Chang et al (2003) has shown this “intensity” rating scale to be essentially equivalent to a “frequency” rating scale (i.e., “none of the time” to “all of the time”). The recall period for each question is “during the past 7 days” and this time frame has been found to provide more precise information than a 4-week time frame (Lai et al 2009). All FACIT scales are scored so that a high score is good. As each of the 12 items of the FAACT anorexia/cachexia-specific subcale ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response. All responses are added with equal weight to obtain the total score. In cases where some answers may be missing, a total score is prorated from the score of the answered items, so long as more than 50% of the items (i.e., at least 7 of 12) were answered. The FAACT was developed with input from both patients and clinicians. Semistructured interviews conducted with 10 patients and 5 practitioners generated 32 candidate anorexia/cachexia items (Cella et al 1993). The practitioners who helped generate the items were also later asked to review the entire list of items. The items underwent multiple iterative reviews to reduce redundancy and clarify wording, resulting in a final list of 18 anorexia/ cachexia items. These items were then pilot tested in 10 cancer and 6 HIV-infected patients with anorexia/cachexia. Patients were asked to rate each item in terms of importance (0, not at all important to 4, very important). All items were found to be sufficiently important for retention in the next stage. The FAACT was then validated in a randomized trial comparing 200mg vs. 800mg per day of megestrol acetate oral suspension in 213 patients with cancer (n=155) or HIV (n=58) (Ribaudo et al 2001). The majority of the cancer patients had non small cell lung cancer. The FAACT was administered by computer at baseline and at weeks 4 and 12. The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) was administered at weeks 4 and 12 only. The anorexia/cachexia subscale was reduced from 18 to 12 items. Items were removed because they were conceptually dissimilar to eating concerns (e.g., “I have diarrhea”) or minimally correlated with the total score (e.g., “I enjoy eating breakfast”). The Cronbach’s coefficient alpha did not change significantly with removal of those items (from 0.77 for both cancer and HIV patients to 0.76 for cancer and 0.78 for HIV). The correlation between 18-item and 12-item scores was 0.94. Scores on the 12-item subscale significantly differed between groups defined by ECOG PSR and were sensitive to change in PSR. MEASURE NAME: Functional Assessment of Anorexia/Cachexia Treatment (FAACT) VERSION: 4 NUMBER OF ITEMS: 39 PATIENT POPULATION: Cancer patients 18 years and older experiencing anorexia/cachexia RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Anorexia/Cachexia Subscale TIME FOR COMPLETION: 10-15 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available. RELATED MEASURES: peds FAACT , FACIT-AD , FACIT-AI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FAACT can be obtained by registering for permission. Users are not permitted to translate the FAACT without permission from FACIT.org. Permission from FACIT.org to translate the FAACT may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Blauwhoff-Buskermolen, S., Ruijgrok, C., Ostelo, R., de Vet, H., Verheul, H., de van der Schueren, M., & Langius, J. The assessment of anorexia in patients with cancer: cut-off values for the FAACT–A/CS and the VAS for appetite. Support Care Cancer 2016; 24: 661–666. doi: 10.1007/s00520-015-2826-2. Change, V., Xia,Q, & Kasimis, B. The Functional Assessment of Anorexia/ Cachexia Therapy (FAACT) Appetite Scale in Veteran Cancer Patients. The Journal of Supportive Oncology 2005; 3(5): 377-382. Gelhorn, H., Gries, K., Speck, R., Duus, E., Bourne, R., Aggarwal, D., & Cella, D. Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subcale (A/CS) in lung cancer patients with involuntary weight loss. Quality of Life Research 2019; 28(6): 1641-1653. doi: 10.1007/s11136-019-02135-7. Lai, J-S., Cella, D., Peterman, A., Barocas, J., & Goldman, S. Anorexia/Cachexia related QOL for children with cancer: Testing the psychometric properties of the pediatric functional assessment of anorexia and cachexia therapy (peds-FAACT). Cancer 2005; 104(7): 1531-1539. LeBlanc, T., Samsa, G., Wolf, S., Locke, S., Cella, D., & Abernethy, A. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). Support Care Cancer 2015; 23: 2341–2347. doi 10.1007/s00520-015-2606-z. Ribaudo, J., Cella, D., Hahn, E., Lloyd, S., Tchekmedyian, N., Von Roenn, J., & Leslie, W. Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Quality of Life Research 2001; 1137-1146. Salsman, J., Beaumont, J., Wortman, K., Yan, Y., Friend, J., & Cella, D. Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Supportive Care in Cancer 2015; 23 (5): 1355-1364. doi: 10.1007/s00520-014-2484-9. Yennurajalingam, S., Frisbee-Hume, S., Palmer, J., Delgado-Guay, M., Bull, J., Phan, A., Tannir, N., Litton, J., Reddy, A., Hui, D., Dalal, S., Massie, L., Reddy, S., & Bruera, E. Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer. Journal of Clinical Oncology 2013; 31(25): 3076-3082doi: 10.1200/JCO.2012.44.4661. Zhou,T., Yang,K., Thapa, S., Fu, Q, Jiang, Y. , & Yu, S. Validation of the Chinese version of functional assessment of anorexia-cachexia therapy (FAACT) scale for measuring quality of life in cancer patients with cachexia. Support Care Cancer 2017; 25: 1183–1189. doi: 10.1007/s00520-016-3508-4. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., & Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., & Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures peds FAACT Pediatric Functional Assessment of Anorexia/Cachexia Treatment LEARN MORE FACIT-AD Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort LEARN MORE FACIT-AI Functional Assessment of Chronic Illness Therapy - Ascites Index LEARN MORE

Download this measure in English. BACK FACIT-TS-G English Downloads Download PDF Download DOC

Download this measure in English. BACK FACT-HN English Downloads Download PDF Download DOC

FBlSI Functional Assessment of Cancer Therapy Bladder Cancer Symptom Index - 7 Item Version For patients with Bladder cancer; a FACT-Bladder Symptom Index (a subset of FACT-Bl containing 7 items) LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details of the FBlSI: MEASURE NAME: Functional Assessment of Cancer Therapy Bladder Cancer Symptom Index - 7 Item Version (FBlSI) VERSION: 4 NUMBER OF ITEMS: 7 PATIENT POPULATION: Bladder cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administeration and interview when applicable SUBSCALE DOMAINS: Bladder Cancer Subscale TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FACT-Bl , FACT-Bl-Cys , NFBlSI-18 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FBlSI can be obtained by registering for permission. Users are not permitted to translate the FBlSI without permission from FACIT.org. Permission from FACIT.org to translate the FBlSI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-Bl Functional Assessment of Cancer Therapy – Bladder LEARN MORE FACT-Bl-Cys Functional Assessment of Cancer Therapy – Bladder – Cystectomy LEARN MORE NFBlSI-18 Functional Assessment of Cancer Therapy – Bladder – Cystectomy LEARN MORE

FKSI-15 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version For patients with Kidney Cancer, a 15 item scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FKSI-15 is a brief symptom index for assessing quality of life for advanced kidney cancer patients comprised of items from the FACIT Measurement System. It is composed of 15 items, nine of which assess disease-related symptoms specific to kidney cancer and six of which relate to other cancer patient concerns. MEASURE NAME: Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version (FKSI-15) VERSION: 4 NUMBER OF ITEMS: 15 PATIENT POPULATION: Kidney cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Kidney cancer symptom index TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: NFKSI-19 , FKSI-DRS , FKSI-10 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FKSI-15 can be obtained by registering for permission. Users are not permitted to translate the FKSI-15 without permission from FACIT.org. Permission from FACIT.org to translate the FKSI-15 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bukowski, R., Cella, D., Gondek, K., Escudier, B. Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer. American Journal of Clinical Oncology; 2007: 30(3): 220-227. doi: 10.1097/01.coc.0000258732.80710.05. Butt, Z., Peipert, D., Webster, K., Chen, C., & Cella, D. General population norms for the functional assessment of cancer therapy – kidney symptom index (FKSI). Cancer 2013; 119(2): 429-437. doi: 10.1002/cncr.27688. Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Yount, S., Brucker, P., Du, H., Bukowski, R., Vogelzang, N., Bro, W. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value in Health 2007; 10(4): 285-293. doi: 10.1111/j.1524-4733.2007.00183.x. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Cella, D., Escudier, B., Rini, B., Chen, C., Bhattacharyya, H., Tarzai, J., Rosbrook, B., Kim, S., & Motzer, R. Patient-reported outcomes for axitinib v sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British Journal of Cancer 2013; 108(8): 1571–1578. doi: 10.1038/bjc.2013. Luo, X., Cappelleri, J., Cella, D., Li, J., Charbonneau, C., Kim, S., Chen, I., & Motzer, R. Using the Rasch model to validate and enhance the interpretation of the functional assessment of cancer therapy-kidney symptom index-disease related symptoms scale. Value in Health 2009; 12(4): 580-586. doi: 10.1111/j.1524-4733.2008.00473.x. Motzer, R. , Hutson, T., Olsen, M., Hudes, G., Burke, J., Edenfield, W., Wilding, Agarwal, N., Thompson, J., Cella, D., Bello, A., Korytowksy, B., Yuan, J., Valota, O., Martell, B., Hariharan, S., & Figlin, R. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. Journal of Clinical Oncology 2012; 30(12): 1371-1377. doi: 10.1200/JCO.2011.36.4133. Rini, B., Wilding, G., Hudes, G., Stadler, W., Kim, S., Tarazi, J., Rosbrook, B., Trask, P., Wood, L., & Dutcher, J. Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology 2009; 27(27): 4462-4468. doi: 10.1200/JCO.2008.21.7034. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures NFKSI-19 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version LEARN MORE FKSI-DRS Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms LEARN MORE FKSI-10 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version LEARN MORE

FACT-ICM-17 Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17 Item Symptom Index For patients receiving immunotherapy treatment LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT-ICM-17 is a brief, validated measure developed to assess the most common, distressing, and clinically useful symptomatic ICM-related immune-related adverse events. It is appropriate for use in research as well as routine symptom monitoring and management. MEASURE NAME: Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17 Item Symptom Index VERSION: 1 NUMBER OF ITEMS: 17 PATIENT POPULATION: Cancer patients 18 years and older receiving immunotherapy treatment RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: ICM TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, total score possible RELATED MEASURES: FACT-ICM , FACT- G, FACT-RNT DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-ICM-17 can be obtained by registering for permission. Users are not permitted to translate the FACT-ICM-17 without permission from FACIT.org. Permission from FACIT.org to translate the FACT-ICM-17 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Gudenkauf LM, Tometich DB, Hoogland AI, Li XY, Kirtane K, Small BJ, Barata A, Gonzalez BD, Chung CH, Shafique MR, Gray J, Khushalani NI, Postow MA, Cella D, Webster KA, Dicker AP, Jim HSL. Validation of the Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator 17-Item Symptom Index (FACT-ICM-17) to Facilitate Implementation in Research and Clinical Care. Available at SSRN: https://ssrn.com/abstract=5034323 or http://dx.doi.org/10.2139/ssrn.5034323 Hansen AR, Ala-Leppilampi K, McKillop C, Siu LL, Bedard PL, Abdul Razak AR, Spreafico A, Sridhar SS, Leighl N, Butler MO, Hogg D, Sacher A, Oza AM, Al-Agha R, Maurice C, Chan CT, Shapera S, Feld JJ, Nisenbaum R, Webster K, Cella D, Parsons J. Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer. 2020 Apr 1;126(7):1550-1558. doi: 10.1002/cncr.32692. Epub 2020 Jan 8. PMID: 31914209. Webster KA, O’Connor ML, Hansen AR, Kircher S, Jim HSL, Dicker AP, Janda M, Ala-leppilampi K, Bingham CO III, Feliciano J, Henry NL, Steffen McLouth LE, Cella D. Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. J Cancer Metastasis Treat 2020;6:8. http://dx.doi.org/10.20517/2394-4722.2019.38. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-ICM Functional Assessment of Cancer Therapy – Immune Checkpoint Modulator LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy LEARN MORE

View all available languages for this measure. BACK FACT-CNS Languages Dutch English French German Italian Korean Norwegian Spanish Swedish

FACT-Br-CI Functional Assessment of Cancer Therapy – Brain Cognitive Index For patients with Brain cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT-Br-CI measures self-reported cognition in patients with brain cancer. Studies that included the FACT-Br could be retrospectively analyzed to assess subjective cognitive outcomes, enriching the information from prior research. Integration of the FACT-Br-CI in routine clinical care may be an efficient method of monitoring cognition. MEASURE NAME: Functional Assessment of Cancer Therapy – Brain Cognitive Index (FACT-Br-CI) VERSION: 4 NUMBER OF ITEMS: 9 PATIENT POPULATION: Brain cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Cognitive Index TIME FOR COMPLETION: 5 minutes SCORING: Manual scoring template, some items are reverse scored. RELATED MEASURES: FBrSI , NFBrSI-24 , FACT-Br DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-Br-CI can be obtained by registering for permission. Users are not permitted to translate the FACT-Br-CI without permission from FACIT.org. Permission from FACIT.org to translate the FACT-Br-CI may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Zarrella GV, Perez A, Dietrich J, Parsons MW. Reliability and validity of a novel cognitive self-assessment tool for patients with cancer. Neurooncol Pract . 2021 Jul 21;8(6):691-698. doi: 10.1093/nop/npab045. PMID: 34777838; PMCID: PMC8579089. Weitzner, M.A., Meyers, C.A., Gelke, C., Byrne, K., Cella, D.F., & Levin, V.A. The Functional Assessment of Cancer Therapy (FACT) Scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995; 75(5): 1151-1161. Thavarajah, N., Bedard, G., Zhang, L., Cella, D., Beaumont, J., Tsao, M., Barnes, E., Danjoux, C., Sahgal, A., Soliman, H., & Chow, E. The Functional Assessment of Cancer Therapy – Brain (FACT-Br) for assessing quality of life in patients with brain metastases: A comparison of recall periods. Journal of Pain Management 2013; 6(3): 223-234. Thavarajah, N., G., Zhang, L., Cella, D., Beaumont, J. Tsao, M., Barnes, E., Danjoux, C., Sahgal, A., Soliman, H., & Chow, E. Psychometric validation of the functional assessment of cancer therapy—brain (FACT-Br) for assessing quality of life in patients with brain metastases Supportive Care in Cancer 2014; 22 (4): 1017-1028. doi: 10.1007/s00520-013-2060-8. Verhaak, E., Schimmel, W. C., Sitskoorn, M. M., Bakker, M., Hanssens, P. E., & Gehring, K. (2019). Multidimensional assessment of fatigue in patients with brain metastases before and after Gamma Knife radiosurgery. Journal of neuro-oncology , 144 (2), 377-384. Verhaak, E., Gehring, K., Hanssens, P. E., & Sitskoorn, M. M. (2019). Health-related quality of life of patients with brain metastases selected for stereotactic radiosurgery. Journal of neuro-oncology , 143 (3), 537-546. Verhaak, E., Schimmel, W. C., Gehring, K., Emons, W. H., Hanssens, P. E., & Sitskoorn, M. M. (2020). Health-related quality of life after Gamma Knife radiosurgery in patients with 1–10 brain metastases. Journal of Cancer Research and Clinical Oncology , 1-11. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FBrSI Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 15 Item Version LEARN MORE NRBrSI-24 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Brain Cancer Symptom Index - 24 Item Version LEARN MORE FACT-Br Functional Assessment of Cancer Therapy – Brain LEARN MORE

Download this measure in English. BACK PROMIS Pool v1.0 - Dyspnea Emotional Response English Downloads Download PDF Download DOC

MICRA Multidimensional Impact of Cancer Risk Assessment For patients who have undergone genetic testing for risk of cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Multidimensional Impact of Cancer Risk Assessment (MICRA) is a tool to measure the specific impact of result disclosure after genetic testing. The authors compared its performance with that of questionnaires measuring general and cancer-specific distress. Participants (158 females) responded 1 month after they received genetic test results. They were divided into 4 standard clinical test result groups: BRCA1/2 positive, BRCA1/2 negative, panel negative, and true negative. Factor analysis supported the formation of 3 subscales: Distress, Uncertainty, and Positive Experiences. All 3 MICRA subscales differentiated participants who were BRCA1/2 positive from the other 3 groups. MICRA thus helps identify subgroups of vulnerable genetic testing participants. MEASURE NAME: Multidimensional Impact of Cancer Risk Assessment (MICRA) VERSION: 1 NUMBER OF ITEMS: 25 PATIENT POPULATION: Patients 18 years and older who have received cancer-related genetic testing RECALL PERIOD: Past 7 days RESPONSE SCALE: 4 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Distress, Uncertainty, Positive Experiences TIME FOR COMPLETION: Not available SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-G , FACT-G7 , FANLTC DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the MICRA can be obtained when licensing the measure. Users are not permitted to translate the MICRA without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the MICRA. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella D, Hughes C, Peterman A, Chang CH, Peshkin BN, Schwartz MD, Wenzel L, Lemke A, Marcus AC, Lerman C. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol . 2002 Nov;21(6):564-72. LICENSE THIS MEASURE Related Measures Related Measures FACT-G Functional Assessment of Cancer Therapy - General LEARN MORE FACT-G7 Functional Assessment of Cancer Therapy – General – 7 Item Version LEARN MORE FANLTC Functional Assessment of Non-Life Threatening Conditions LEARN MORE